A new strategy for 2021 to 2026
We've launched our new strategic plan.
The new strategy sets out how we'll work across the health and care system and life sciences sector to develop our products, processes, partnerships and people.
Find out more
- We've identified 4 overarching strategic pillars for the next 5 years. They show the areas we believe we'll have the biggest impact.
- Read about our new 5-year strategy.
Guidance
Evidence-based recommendations developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Get involved
We want you to be involved in our work. Tell us what matters to you, your organisation or your community.
There are many ways you can get involved as a healthcare professional or a member of the public.
About us
Find out more about
and how we support
Latest news
-
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today
-
NICE has today (2 June 2021) published draft guidance for public consultation which does not recommend risdiplam (also called Evrysdi and made by Roche) for treating the rare genetic disorder spinal muscular atrophy (SMA).
-
NICE has updated its advice on two therapeutics for managing COVID-19 – remdesivir and colchicine.
-
The long-term safety and efficacy is inadequate on two procedures NICE is calling for further evidence on
Explore NICE
Into practice
Resources to help you use our guidance and quality standards
Financial planning
Advice and tools to help you make the best use of your resources
Antimicrobial resistance
View our antimicrobial prescribing guidelines
Our role in patient safety
Our guidelines make evidence-based, best practice recommendations.
Find journals and databases
Access to a range of journals and other evidence-based resources.